http://www.lctglobal.com/upload/news...%20implant.pdf

Successful second implant of NTCELL for Parkinson’s
18 August 2014 – Sydney, Australia and Auckland, New Zealand –
Living Cell Technologies
Limited today announced
that a second patient has been successfully implanted at Auckland City
Hospital in the clinical trial of the regenerative cell therapy NTCELL
®
for Parkinson’s disease. LCT
plans to complete the patient treatment phase of the study this year.
The Phase I/IIa clinical trial is
an open-label investigation of the safety and clinical effects of NTCELL
in patients who can no longer respond to current
therapy. The trial is directed by Dr Barry Snow
MBChB, FRACP, FRCPC, an internationally recognised
clinician and researcher in Parkinson’s disease
who leads the Auckland Movement Disorders Clinic
at the Auckland District Health Board.
Dr Ken Taylor, CEO of LCT says, “A great deal of
hard work, preclinical research and scientific
endeavour has gone into the discovery and developm
ent of NTCELL. Our innovative approach is the
first to target regeneration of brain cells for
patients who are failing the current conventional
treatment for Parkinson’s disease.”
– Ends –
For further information:
www.lctglobal.com
At the company:
Ken Taylor
Chief Executive
Tel: +64 9 276 2690
Mobile: +64 21 796000
ktaylor@lctglobal.com
Media enquires:
Rachael Joel
Botica Butler Raudon Partners
Tel: +64 9 303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz
About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian
biotechnology company researching and developing
cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL
®
is an
alginate coated capsule containing clusters of
neonatal porcine choroid plexus cells. After
transplantation NTCELL functions as a biological factory producing nerve growth factors to promote
new central nervous system growth and repair disease induced nerve degeneration.
NTCELL is in Phase I/IIa clinical trial in New Zealan
d for the treatment of Parkinson’s disease. It has
the potential to be used in a number of othe
r central nervous system indications such as
Huntington’s, Alzheimer’s and motor neurone diseases.